^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

[Lymphoplasmacytic lymphoma: a clinicopathological and prognostic analysis of 27 cases]

Published date:
12/08/2021
Excerpt:
Twenty-seven cases of LPL from January 2016 to December 2020 at Guangdong Provincial People's Hospital were collected...The positive rate of MYD88 L265P mutation was 73.9% (17/23). Most of the patients were treated with rituximab...Most of the patients were treated with rituximab combined with alkylating agents, nucleoside analogues or immunomodulators, and the few patients with relapse or progression...
Secondary therapy:
Alkylating agent; Nucleoside analog; Immunomodulator
DOI:
10.3760/cma.j.cn112151-20210316-00208